Site Search

News

Investors

Normal

Press release year list 2021 2020 2019 2018 2017 2016 2015 2014

01/13/2021

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)

DownloadPDF format download (opens in new window)

01/06/2021

Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference

DownloadPDF format download (opens in new window)

Contact Us

Sasha Damouni Ellis
VP, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.

info@marinuspharma.com
484-253-6792(o)
484-801-4669(f)

Quick Links

SEC Filings
Investor FAQs

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Marinus Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Marinus Pharmaceuticals to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options *

News

Events & Presentations

Quarterly Reports

Annual Reports

SEC Filings

End of Day Stock Quote

Unsubscribe